About: Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients
Creator	Chu, Yanhui Wang, Quanyi Li, Jing Wang, Xiaoli Pan, Yang Feng, Yingmei Guo, Xianghua Hu, Yaling Prof, Asso Xin, Qianqian
Source	Medline; PMC
abstract	BACKGROUND: COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The urgent needs for exploring the neutralizing antibodies from patients with different clinical characteristics are emerging. METHODS: A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. Antibodies were determined with a modified cytopathogenic neutralization assay (NA) based on live SARS-CoV-2 and enzyme linked immunosorbent assay (ELISA). The dynamics of neutralizing antibody levels at different time points with different clinical characteristics were analyzed. RESULTS: The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till day 41-53. The total GMT was 1:163.7 (95% CI, 128.5 to 208.6) by NA and 1:12441.7 (95% CI, 9754.5 to 15869.2) by ELISA. The antibody level by NA and ELISA peaked on day 31-40 since onset, and then decreased slightly. In multivariate GEE analysis, patients at age of 31-45, 46-60, and 61-84 had a higher neutralizing antibody level than those at age of 16-30 (β=1.0470, P=0.0125; β=1.0613, P=0.0307; β=1.3713, P=0.0020). Patients with a worse clinical classification had a higher neutralizing antibody titer (β=0.4639, P=0.0227). CONCLUSIONS: The neutralizing antibodies were detected even at the early stage of disease, and a significant response showed in convalescent patients.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1093/cid/ciaa721
bibo:pmid	32497196
has license	no-cc
sha1sum (hex)	d17e70454dfb0b053009a3d20ec44a700a109e16
schema:url	https://doi.org/10.1093/cid/ciaa721
resource representing a document's title	Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients
has PubMed Central identifier	PMC7314147
has PubMed identifier	32497196
schema:publication	Clin Infect Dis
resource representing a document's body	covid:d17e70454dfb0b053009a3d20ec44a700a109e16#body_text
is schema:about of	named entity 'vaccines' named entity 'COVID' named entity 'titer' named entity 'random sampling' named entity 'standard deviation' named entity 'serum' named entity 'plasma' named entity 'SARS-CoV-2' named entity 'Capital Medical University' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'titer' named entity 'seropositivity' named entity 'SARS-CoV-2 virus' named entity 'Cytopathic effect' named entity 'MERS-CoV' named entity 'Neutralizing antibodies' named entity 'GMT' named entity 'data analysis' named entity 'virus' named entity 'Medical Ethical' named entity 'COVID-19' named entity 'COVID-19' named entity 'neutralizing antibody' named entity 'macaques' named entity 'blood sample' named entity 'Serum samples' named entity 'quarantine' named entity 'informed consent' named entity 'pseudovirus' named entity 'titer' named entity 'CO2' named entity 'rapid diagnostic' named entity 'SARS-CoV-2' named entity '1:64' named entity 'single-stranded' named entity 'antiviral' named entity 'serum samples' named entity 'GMT' named entity 'virus' named entity 'Coronaviridae' named entity 'logit' named entity 'therapeutic agents' named entity 'neutralizing antibody' named entity '95% CI' named entity 'cardiovascular disease' named entity 'enzyme linked immunosorbent assay' named entity 'antibody' named entity 'antibody' named entity '95% CI' named entity 'asymptomatic infections' named entity 'Vero cells' named entity 'Beijing' named entity 'neutralizing antibody' named entity 'antibody' named entity 'vaccines' named entity 'coronavirus disease 2019' named entity 'serum' named entity 'Fisher's exact test' named entity '36.5°C' named entity 'antibodies' named entity 'COVID' named entity 'GMT' named entity 'Chi-square test' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'seropositivity' named entity 'contact tracing' named entity 'neutralizing antibodies' named entity 'COVID' named entity 'safe and effective' named entity 'seropositivity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software